Abstract:Conclusions Taken together, these genetic and functional data strongly support the conclusion that mutations in an enhancer element in ALAS2 intron 1 that contains a GATA-binding site result in a clinical phenotype similar to patients with XLSA owing to mutations in the ALAS2 coding sequence itself. In our own survey of >125 probands with CSA (Ref. 2 and data not shown), ALAS2 intron 1 enhancer element mutations constitute _3% of all probands and _5% of cases of XLSA. For this reason, we suggest that ALAS2 intron 1 GATAbinding site variants can be excluded in males with hypochromic, microcytic, nonsyndromic sideroblastic anemias lacking coding mutations in ALAS2 or biallelic coding or splicing variants in SLC25A38, particularly those with clinical or laboratory evidence of X-linkage or a minimal, but discernable, response to pyridoxine therapy.

X‐linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA‐binding site mutations